Last reviewed · How we verify

Liraglutide Pen Injector [Saxenda]

University College, London · FDA-approved active Small molecule

Liraglutide Pen Injector [Saxenda] is a GLP-1 receptor agonist Small molecule drug developed by University College, London. It is currently FDA-approved for Chronic weight management in adults with obesity or overweight with weight-related comorbidities. Also known as: Saxenda, Victoza, Liraglutide 3mg.

Liraglutide activates GLP-1 receptors in the brain and pancreas to reduce appetite, increase satiety, and promote weight loss.

Liraglutide activates GLP-1 receptors in the brain and pancreas to reduce appetite, increase satiety, and promote weight loss. Used for Chronic weight management in adults with obesity or overweight with weight-related comorbidities.

At a glance

Generic nameLiraglutide Pen Injector [Saxenda]
Also known asSaxenda, Victoza, Liraglutide 3mg
SponsorUniversity College, London
Drug classGLP-1 receptor agonist
TargetGLP-1R (GLP-1 receptor)
ModalitySmall molecule
Therapeutic areaEndocrinology / Obesity
PhaseFDA-approved

Mechanism of action

Liraglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1, a hormone that regulates blood glucose and appetite. By binding to GLP-1 receptors in the hypothalamus and other brain regions, it decreases hunger signals and increases feelings of fullness. At higher doses (as in Saxenda), the weight-loss effect predominates over glucose control.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Liraglutide Pen Injector [Saxenda]

What is Liraglutide Pen Injector [Saxenda]?

Liraglutide Pen Injector [Saxenda] is a GLP-1 receptor agonist drug developed by University College, London, indicated for Chronic weight management in adults with obesity or overweight with weight-related comorbidities.

How does Liraglutide Pen Injector [Saxenda] work?

Liraglutide activates GLP-1 receptors in the brain and pancreas to reduce appetite, increase satiety, and promote weight loss.

What is Liraglutide Pen Injector [Saxenda] used for?

Liraglutide Pen Injector [Saxenda] is indicated for Chronic weight management in adults with obesity or overweight with weight-related comorbidities.

Who makes Liraglutide Pen Injector [Saxenda]?

Liraglutide Pen Injector [Saxenda] is developed and marketed by University College, London (see full University College, London pipeline at /company/university-college-london).

Is Liraglutide Pen Injector [Saxenda] also known as anything else?

Liraglutide Pen Injector [Saxenda] is also known as Saxenda, Victoza, Liraglutide 3mg.

What drug class is Liraglutide Pen Injector [Saxenda] in?

Liraglutide Pen Injector [Saxenda] belongs to the GLP-1 receptor agonist class. See all GLP-1 receptor agonist drugs at /class/glp-1-receptor-agonist.

What development phase is Liraglutide Pen Injector [Saxenda] in?

Liraglutide Pen Injector [Saxenda] is FDA-approved (marketed).

What are the side effects of Liraglutide Pen Injector [Saxenda]?

Common side effects of Liraglutide Pen Injector [Saxenda] include Nausea, Vomiting, Diarrhea, Constipation, Headache, Injection site reactions.

What does Liraglutide Pen Injector [Saxenda] target?

Liraglutide Pen Injector [Saxenda] targets GLP-1R (GLP-1 receptor) and is a GLP-1 receptor agonist.

Related